FDA approval sets up BMS’s Sotyktu as oral therapy of choice in psoriasis

Strong efficacy data and a clean label put Bristol Myers’ Sotyktu deucravacitinib in pole position to quickly become the oral standard of care for plaque psoriasis.

Late Friday, FDA approved the first-in-class TYK2 inhibitor to treat moderate-to-severe plaque psoriasis, making it the second oral therapy approved for the indication after Otezla apremilast. ...